Psy­che­delics start­up nets more than $10M in seed fund­ing as it looks to make a splash

As com­pa­nies small and large be­gin to test the wa­ters and go main­stream with a se­ries of dif­fer­ent psy­che­delics, one start­up is hop­ing to use an ex­pert in the field to ad­vance a ther­a­py us­ing ke­t­a­mine for ma­jor de­pres­sive dis­or­der.

Free­dom Bio­sciences, a clin­i­cal-stage com­pa­ny de­vel­op­ing ther­a­peu­tics us­ing ke­t­a­mine and oth­er psy­che­delics, has net­ted it­self $10.5 mil­lion in seed fi­nanc­ing.

The com­pa­ny was found­ed last April by John Krys­tal, the chair of the De­part­ment of Psy­chi­a­try at Yale Uni­ver­si­ty, and Di­na Burk­it­baye­va, co-founder of PsyMed Ven­tures. Burk­it­baye­va now serves as the start­up’s CEO, while Krys­tal serves as chief sci­en­tif­ic ad­vi­sor.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN